Pricing

FibroGen Inc (FGEN)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Enrique A. Conterno
Employees:
570
409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158
415-978-1200
FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available